Top

Published in:

01-12-2020 | Multiple Sclerosis | Original Communication

Parity and disability progression in relapsing–remitting multiple sclerosis

Authors: Anat Achiron, Alon Ben-David, Michael Gurevich, David Magalashvili, Shay Menascu, Mark Dolev, Yael Stern, Tomer Ziv-Baran, for the Israeli Multiple Sclerosis Pregnancy Study Group (IMSPSG)

Published in: Journal of Neurology | Issue 12/2020

Abstract

Aim

It is unclear whether parity and increasing parity are risk factors for long-term disability progression in relapsing–remitting multiple sclerosis. Furthermore, data on the effects of immunomodulatory treatments in this context are limited.

Objectives

To examine the association between parity and long-term neurological sequela among relapsing-remitting multiple sclerosis patients.

Methods

A cohort study including all women with relapsing–remitting multiple sclerosis in Israel registered in Sheba Medical Center Multiple Sclerosis data registry from 1995 to 2018. The risks of progression to moderate and severe disability according to parity after disease onset were evaluated. Cox regression models using childbirth as a time-dependent covariate were used to study the association between parity and disability progression.

Results

During the 26,785 person-years of follow-up a total of 2281 women were included in the study. Parity was associated with decreased risk of progression to moderate (adj.HR, 0.68; 95% CI 0.54–0.85, P = 0.001) but not to severe disability (adj.HR, 0.88; 95% CI 0.68–1.14, P = 0.36). Hazard ratios for progression to moderate and severe disability were comparable between women with one, two, and three or more births. In a subgroup analysis of women who gave birth within 5 years of disease onset, immunomodulatory treatment did not affect moderate or severe disability-free survival.

Conclusion

This study suggests that childbirth after the onset of multiple sclerosis is associated with a decreased risk of progression to moderate neurological disability.

Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169–180. https://doi.org/10.1056/NEJMra1401483CrossRefPubMedPubMedCentral

Achiron A, Gurevich M (2009) Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways. J Neurol Sci 286(1–2):47–53. https://doi.org/10.1016/j.jns.2009.06.038CrossRefPubMed

Kalincik T (2015) Multiple sclerosis relapses: epidemiology, outcomes and management. Syst Rev Neuroepidemiol 44(4):199–214. https://doi.org/10.1159/000382130CrossRef

Finkelsztejn A, Brooks J, Paschoal F, Fragoso Y (2011) What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 118(7):790–797. https://doi.org/10.1111/j.1471-0528.2011.02931.xCrossRefPubMed

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339(5):285–291CrossRef

Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C, Pregnancy In Multiple Sclerosis Group (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(6):1353–1360. https://doi.org/10.1093/brain/awh152CrossRefPubMed

D’hooghe MB, Nagels G (2010) Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 81(1):38–41. https://doi.org/10.1136/jnnp.2008.163816CrossRefPubMed

D’hooghe M, Haentjens P, Nagels G, D’Hooghe T, De Keyser J (2012) Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 259(5):855–861. https://doi.org/10.1007/s00415-011-6267-7CrossRefPubMed

Msera S, Cavalla P, Prosperini L, Mattioda A, Mancinelli CR, Superti G et al (2015) Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler 21(10):1291–1297. https://doi.org/10.1177/1352458514561907CrossRef

10.

Achiron A, Sarova-Pinhas I, Magalashvili D, Stern Y, Gal A, Dolev M et al (2019) Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy. Mult Scler 25(13):1746–1753. https://doi.org/10.1177/1352458518809903CrossRefPubMed

11.

Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R et al (2005) Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 89(3):265–270. https://doi.org/10.1007/s10549-004-2229-4CrossRefPubMed

12.

Harel Y, Kalron A, Menascu S, Magalashvili D, Dolev M, Doniger G, Simon E, Achiron A (2019) Cognitive function in multiple sclerosis: a long-term look on the bright side. PLoS ONE 14(8):e0221784. https://doi.org/10.1371/journal.pone.0221784CrossRefPubMedPubMedCentral

13.

Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E et al (2013) Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE 8(8):e71058. https://doi.org/10.1371/journal.pone.0071058CrossRefPubMedPubMedCentral

14.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231. https://doi.org/10.1002/ana.410130302CrossRefPubMed

15.

McDonald WI, Compston A, Edan G (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127. https://doi.org/10.1002/ana.1032CrossRefPubMed

16.

Polman CH, Reingold SC, Edan G (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’. Ann Neurol 58(6):840–846. https://doi.org/10.1002/ana.20703CrossRefPubMed

17.

Polman CH1, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral

18.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444CrossRefPubMed

19.

Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264(12):2351–2374. https://doi.org/10.1007/s00415-017-8594-9CrossRefPubMedPubMedCentral

20.

Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343(20):1430–1438. https://doi.org/10.1056/NEJM200011163432001CrossRefPubMed

21.

Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66(2):172–177. https://doi.org/10.1212/01.wnl.0000194259.90286.feCrossRefPubMed

22.

Therneau T, Crowson C and Atkinson E. Using Time Dependent Covariates and Time Dependent Coefficients in the Cox Model. https://cran.r-project.org/web/packages/survival/vignettes/timedep.pdf. Accessed Nov 2018

23.

Matthews WB, Compston A, Allen IV, Martyn CN (eds) (1991) Some aspects of the natural history: Pregnancy. In: McAlpine’s multiple sclerosis, 2nd edn, pp 109–110

24.

Moberg JY, Laursen B, Thygesen LC, Magyari M (2019) Reproductive history of the Danish multiple sclerosis population: a register-based study. Mult Scler 30:1352458519851245. https://doi.org/10.1177/1352458519851245CrossRef

25.

Runmarker B, Andersen O (1995) Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118(pt 1):253–261. https://doi.org/10.1093/brain/118.1.253CrossRefPubMed

26.

Verdru P, Theys P, D'Hooghe MB, Carton H (1994) Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg 96(1):38–41. https://doi.org/10.1016/0303-8467(94)90027-2CrossRefPubMed

27.

Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D (2012) Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 83(8):793–795. https://doi.org/10.1136/jnnp-2012-302848CrossRefPubMed

28.

Koch M, Uyttenboogaart M, Heersema D, Steen C, De Keyser J (2009) Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 80(6):676–678. https://doi.org/10.1136/jnnp.2008.160911CrossRefPubMed

29.

D’Amico E, Leone C, Patti F (2016) Offspring number does not influence reaching the disability’s milestones in multiple sclerosis: a seven-year follow-up study. Int J Mol Sci 17(2):234. https://doi.org/10.3390/ijms17020234CrossRefPubMedPubMedCentral

30.

Figueiredo AS, Schumacher A (2016) The T helper type 17/regulatory T cell paradigm in pregnancy. Immunology 148(1):13–21. https://doi.org/10.1111/imm.12595CrossRefPubMedPubMedCentral

31.

Duarte-Guterman P, Leuner B, Galea LAM (2019) The long and short term effects of motherhood on the brain. Front Neuroendocrinol 53:100740. https://doi.org/10.1016/j.yfrne.2019.02.004CrossRefPubMed

32.

Barha CK, Lieblich SE, Chow C, Galea LA (2015) Multiparity-induced enhancement of hippocampal neurogenesis and spatial memory depends on ovarian hormone status in middle age. Neurobiol Aging 36(8):2391–2405. https://doi.org/10.1016/j.neurobiolaging.2015.04.007CrossRefPubMed

33.

Eid RS, Chaiton JA, Lieblich SE, Bodnar TS, Weinberg J, Galea LAM (2019) Early and late effects of maternal experience on hippocampal neurogenesis, microglia, and the circulating cytokine milieu. Neurobiol Aging 78:1–17. https://doi.org/10.1016/j.neurobiolaging.2019.01.021CrossRefPubMed

34.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D et al (2016) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol 80(1):89–100. https://doi.org/10.1002/ana.24682CrossRefPubMed

Title: Parity and disability progression in relapsing–remitting multiple sclerosis
Authors: Anat Achiron
Alon Ben-David
Michael Gurevich
David Magalashvili
Shay Menascu
Mark Dolev
Yael Stern
Tomer Ziv-Baran
for the Israeli Multiple Sclerosis Pregnancy Study Group (IMSPSG)
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keyword: Multiple Sclerosis
Published in: Journal of Neurology / Issue 12/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10093-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Parity and disability progression in relapsing–remitting multiple sclerosis

Abstract

Aim

Objectives

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aim

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2020

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

The effect of transcranial direct current stimulation on upper limb motor performance in Parkinson’s disease: a systematic review

Ocular lateral deviation with brief removal of visual fixation differentiates central from peripheral vestibular syndrome

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

Yield of the PMP22 deletion analysis in patients with compression neuropathies

Disease progression but not physical state per se determines mental wellbeing in ALS